Molecular Imaging of Diffuse Cardiac Fibrosis with a Radiotracer That Targets Proteolyzed Collagen IV.

Autor: Niego B; From the NanoBiotechnology Laboratory (B.N., R.X., M.E., C.E.H.) and NanoTheranostics Laboratory (E.J., K.A.), Australian Centre for Blood Diseases, Central Clinical School, Monash University, Melbourne, VIC 3004, Australia; Department of Neuroscience, Central Clinical School, Monash University, Melbourne, Australia (B.J.); and School of Chemistry and Bio21 Molecular Science and Biotechnology Institute, University of Melbourne, Melbourne, Australia (N.A.Z., A.N., P.S.D.)., Jupp B; From the NanoBiotechnology Laboratory (B.N., R.X., M.E., C.E.H.) and NanoTheranostics Laboratory (E.J., K.A.), Australian Centre for Blood Diseases, Central Clinical School, Monash University, Melbourne, VIC 3004, Australia; Department of Neuroscience, Central Clinical School, Monash University, Melbourne, Australia (B.J.); and School of Chemistry and Bio21 Molecular Science and Biotechnology Institute, University of Melbourne, Melbourne, Australia (N.A.Z., A.N., P.S.D.)., Zia NA; From the NanoBiotechnology Laboratory (B.N., R.X., M.E., C.E.H.) and NanoTheranostics Laboratory (E.J., K.A.), Australian Centre for Blood Diseases, Central Clinical School, Monash University, Melbourne, VIC 3004, Australia; Department of Neuroscience, Central Clinical School, Monash University, Melbourne, Australia (B.J.); and School of Chemistry and Bio21 Molecular Science and Biotechnology Institute, University of Melbourne, Melbourne, Australia (N.A.Z., A.N., P.S.D.)., Xu R; From the NanoBiotechnology Laboratory (B.N., R.X., M.E., C.E.H.) and NanoTheranostics Laboratory (E.J., K.A.), Australian Centre for Blood Diseases, Central Clinical School, Monash University, Melbourne, VIC 3004, Australia; Department of Neuroscience, Central Clinical School, Monash University, Melbourne, Australia (B.J.); and School of Chemistry and Bio21 Molecular Science and Biotechnology Institute, University of Melbourne, Melbourne, Australia (N.A.Z., A.N., P.S.D.)., Jap E; From the NanoBiotechnology Laboratory (B.N., R.X., M.E., C.E.H.) and NanoTheranostics Laboratory (E.J., K.A.), Australian Centre for Blood Diseases, Central Clinical School, Monash University, Melbourne, VIC 3004, Australia; Department of Neuroscience, Central Clinical School, Monash University, Melbourne, Australia (B.J.); and School of Chemistry and Bio21 Molecular Science and Biotechnology Institute, University of Melbourne, Melbourne, Australia (N.A.Z., A.N., P.S.D.)., Ezeani M; From the NanoBiotechnology Laboratory (B.N., R.X., M.E., C.E.H.) and NanoTheranostics Laboratory (E.J., K.A.), Australian Centre for Blood Diseases, Central Clinical School, Monash University, Melbourne, VIC 3004, Australia; Department of Neuroscience, Central Clinical School, Monash University, Melbourne, Australia (B.J.); and School of Chemistry and Bio21 Molecular Science and Biotechnology Institute, University of Melbourne, Melbourne, Australia (N.A.Z., A.N., P.S.D.)., Noor A; From the NanoBiotechnology Laboratory (B.N., R.X., M.E., C.E.H.) and NanoTheranostics Laboratory (E.J., K.A.), Australian Centre for Blood Diseases, Central Clinical School, Monash University, Melbourne, VIC 3004, Australia; Department of Neuroscience, Central Clinical School, Monash University, Melbourne, Australia (B.J.); and School of Chemistry and Bio21 Molecular Science and Biotechnology Institute, University of Melbourne, Melbourne, Australia (N.A.Z., A.N., P.S.D.)., Donnelly PS; From the NanoBiotechnology Laboratory (B.N., R.X., M.E., C.E.H.) and NanoTheranostics Laboratory (E.J., K.A.), Australian Centre for Blood Diseases, Central Clinical School, Monash University, Melbourne, VIC 3004, Australia; Department of Neuroscience, Central Clinical School, Monash University, Melbourne, Australia (B.J.); and School of Chemistry and Bio21 Molecular Science and Biotechnology Institute, University of Melbourne, Melbourne, Australia (N.A.Z., A.N., P.S.D.)., Hagemeyer CE; From the NanoBiotechnology Laboratory (B.N., R.X., M.E., C.E.H.) and NanoTheranostics Laboratory (E.J., K.A.), Australian Centre for Blood Diseases, Central Clinical School, Monash University, Melbourne, VIC 3004, Australia; Department of Neuroscience, Central Clinical School, Monash University, Melbourne, Australia (B.J.); and School of Chemistry and Bio21 Molecular Science and Biotechnology Institute, University of Melbourne, Melbourne, Australia (N.A.Z., A.N., P.S.D.)., Alt K; From the NanoBiotechnology Laboratory (B.N., R.X., M.E., C.E.H.) and NanoTheranostics Laboratory (E.J., K.A.), Australian Centre for Blood Diseases, Central Clinical School, Monash University, Melbourne, VIC 3004, Australia; Department of Neuroscience, Central Clinical School, Monash University, Melbourne, Australia (B.J.); and School of Chemistry and Bio21 Molecular Science and Biotechnology Institute, University of Melbourne, Melbourne, Australia (N.A.Z., A.N., P.S.D.).

Publikováno v: Radiology. Cardiothoracic imaging [Radiol Cardiothorac Imaging] 2024 Apr; Vol. 6 (2), pp. e230098.

PI3K(p110α) as a determinant and gene therapy for atrial enlargement in atrial fibrillation.

Autor: Ezeani M; NanoBiotechnology Laboratory, Central Clinical School, Australian Centre for Blood Diseases, Monash University, Melbourne, VIC, 3004, Australia. martin.ezeani@monash.edu., Prabhu S; The Alfred, and Baker Heart and Diabetes Institute, Melbourne, Australia.; The University of Melbourne, Melbourne, Australia.

Publikováno v: Molecular and cellular biochemistry [Mol Cell Biochem] 2023 Mar; Vol. 478 (3), pp. 471-490. Date of Electronic Publication: 2022 Jul 28.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Assessment of the epi-pericardial fibrotic substrate by collagen-targeted probes.

Autor: Ezeani M; NanoBiotechnology Laboratory, Australian Centre for Blood Diseases, Central Clinical School, Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, VIC, 3004, Australia., Noor A; School of Chemistry, Bio21 Molecular Science and Biotechnology Institute, University of Melbourne, Melbourne, VIC, 3010, Australia., Donnelly PS; School of Chemistry, Bio21 Molecular Science and Biotechnology Institute, University of Melbourne, Melbourne, VIC, 3010, Australia., Niego B; NanoBiotechnology Laboratory, Australian Centre for Blood Diseases, Central Clinical School, Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, VIC, 3004, Australia., Hagemeyer CE; NanoBiotechnology Laboratory, Australian Centre for Blood Diseases, Central Clinical School, Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, VIC, 3004, Australia. christoph.hagemeyer@monash.edu.

Publikováno v: Scientific reports [Sci Rep] 2022 Apr 05; Vol. 12 (1), pp. 5702. Date of Electronic Publication: 2022 Apr 05.

Collagen-Targeted Peptides for Molecular Imaging of Diffuse Cardiac Fibrosis.

Autor: Ezeani M; NanoBiotechnology Laboratory Australian Centre for Blood Diseases Central Clinical School Monash University Melbourne Australia., Noor A; School of Chemistry Bio21 Molecular Science and Biotechnology Institute University of Melbourne Australia., Alt K; NanoTheranostics Laboratory Australian Centre for Blood Diseases Central Clinical School Monash University Melbourne Australia., Lal S; School of Medical Sciences Faculty of Medicine and Health University of Sydney Australia., Donnelly PS; School of Chemistry Bio21 Molecular Science and Biotechnology Institute University of Melbourne Australia., Hagemeyer CE; NanoBiotechnology Laboratory Australian Centre for Blood Diseases Central Clinical School Monash University Melbourne Australia., Niego B; NanoBiotechnology Laboratory Australian Centre for Blood Diseases Central Clinical School Monash University Melbourne Australia.

Publikováno v: Journal of the American Heart Association [J Am Heart Assoc] 2021 Sep 21; Vol. 10 (18), pp. e022139. Date of Electronic Publication: 2021 Sep 13.